

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

Armenian Hamster Anti-CD3e Monoclonal Antibody, Unconjugated, Clone 145-2C11

RRID:AB_393572

Type: Antibody

Proper Citation

BD Biosciences Cat# 550275, RRID:AB_393572

Antibody Information

URL: http://antibodyregistry.org/AB_393572

Proper Citation: BD Biosciences Cat# 550275, RRID:AB_393572

Target Antigen: CD3e

Clonality: monoclonal

Comments: Flow cytometry, Immunohistochemistry-frozen, Immunohistochemistry-zinc-fixed

Antibody Name: Armenian Hamster Anti-CD3e Monoclonal Antibody, Unconjugated, Clone 145-2C11

Description: This monoclonal targets CD3e

Target Organism: mouse

Clone ID: 145-2C11

Antibody ID: AB_393572

Vendor: BD Biosciences

Catalog Number: 550275

Record Creation Time: 20250820T050349+0000

Record Last Update: 20250820T204104+0000

Ratings and Alerts

No rating or validation information has been found for Armenian Hamster Anti-CD3e Monoclonal Antibody, Unconjugated, Clone 145-2C11.

No alerts have been found for Armenian Hamster Anti-CD3e Monoclonal Antibody, Unconjugated, Clone 145-2C11.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. *Cancer cell*, 43(8), 1512.

Huseni MA, et al. (2023) CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. *Cell reports. Medicine*, 4(1), 100878.

Cortes JR, et al. (2022) Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma. *Cell reports*, 39(3), 110695.

Zeng Q, et al. (2022) Cbl-b restrains priming of pathogenic Th17 cells via the inhibition of IL-6 production by macrophages. *iScience*, 25(10), 105151.

Geng CL, et al. (2022) Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling. *Cell chemical biology*, 29(8), 1260.

Geeraerts X, et al. (2021) Macrophages are metabolically heterogeneous within the tumor microenvironment. *Cell reports*, 37(13), 110171.

Kudo Y, et al. (2020) PKC δ Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. *Cancer cell*, 38(2), 247.

Imanishi T, et al. (2020) mTORC1 Signaling Controls TLR2-Mediated T-Cell Activation by Inducing TIRAP Expression. *Cell reports*, 32(3), 107911.

Perrot I, et al. (2019) Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. *Cell reports*, 27(8), 2411.

Nagai M, et al. (2019) Fasting-Refeeding Impacts Immune Cell Dynamics and Mucosal Immune Responses. *Cell*, 178(5), 1072.

Piper CJM, et al. (2019) Aryl Hydrocarbon Receptor Contributes to the Transcriptional Program of IL-10-Producing Regulatory B Cells. *Cell reports*, 29(7), 1878.

Janela B, et al. (2019) A Subset of Type I Conventional Dendritic Cells Controls Cutaneous Bacterial Infections through VEGF β -Mediated Recruitment of Neutrophils. *Immunity*, 50(4), 1069.

Ma X, et al. (2019) Cholesterol Induces CD8 $^{+}$ T Cell Exhaustion in the Tumor Microenvironment. *Cell metabolism*, 30(1), 143.

Roco JA, et al. (2019) Class-Switch Recombination Occurs Infrequently in Germinal Centers. *Immunity*, 51(2), 337.

Oh SA, et al. (2019) Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells. *Current protocols in immunology*, 124(1), e69.

Bauché D, et al. (2018) LAG3 $^{+}$ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1 $^{+}$ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis. *Immunity*, 49(2), 342.

Cortes JR, et al. (2018) RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. *Cancer cell*, 33(2), 259.

Gawden-Bone CM, et al. (2018) PIP5 Kinases Regulate Membrane Phosphoinositide and Actin Composition for Targeted Granule Secretion by Cytotoxic Lymphocytes. *Immunity*, 49(3), 427.